In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

The advanced functional class and the variables of poor prognosis in pulmonary hypertension

Session Poster Session 1

Speaker Adrian Lescano

Congress : Heart Failure 2016

  • Topic : valvular, myocardial, pericardial, pulmonary, congenital heart disease
  • Sub-topic : Pulmonary Hypertension
  • Session type : Poster Session
  • FP Number : P487

Authors : A Lescano (Buenos Aires,AR), L Talavera (Buenos Aires,AR), J Mazzei (Buenos Aires,AR), E Barimboim (Buenos Aires,AR), V Saurit (BUENOS AIRES,AR), B Varela (Buenos Aires,AR), D Haag (Buenos Aires,AR), C Botta (Buenos Aires,AR), V Rios (Buenos Aires,AR), G Giacomi (Buenos Aires,AR)

A Lescano1 , L Talavera1 , J Mazzei2 , E Barimboim2 , V Saurit3 , B Varela2 , D Haag4 , C Botta5 , V Rios5 , G Giacomi5 , 1Sociedad Argentina de Cardiologia - Buenos Aires - Argentina , 2SOCIEDAD ARGENTINA DE MEDICINA RESPIRATORIA - Buenos Aires - Argentina , 3SOCIEDAD ARGENTINA DE REUMATOLOGIA - BUENOS AIRES - Argentina , 4Sociedad Argentina de Pediatria - Buenos Aires - Argentina , 5Federacion Argentina de Cardiologia - Buenos Aires - Argentina ,

On behalf: RECOPILAR

European Journal of Heart Failure Abstracts Supplement ( 2016 ) 18 ( Supplement 1 ), 122

Introduction: Pulmonary arterial hypertension (PAH) is a multifactorial disease associated with high morbidity and mortality. However, the diagnosis and therapeutics strategies used in most of the Argentinean regions are poorly known. The advanced functional class (FC) is an indicator of poor prognosis and one of the therapeutic goals. Aims: 1-To determine the impact of advanced FC in patients with PAH on established markers of poor prognosis, such as clinical, biomarker, hemodynamic, and echocardiographic parameter 2-To compare treatment strategies between an advanced and non advanced FC Method: Between July 2014 and May 2015, 170 patients with confirmed PAH were prospectively included in a multicenter, collaborative, observational registry by 60 investigators from 20 provinces in Argentina. Inclusion criteria were as follows: 1-patients over three months of age; 2-mean pulmonary arterial pressure (mPAP) at rest ≥ 25 mmHg by right heart catheterization (RHC) and 3 - clinical stability in the absence of hospitalization in last month. WHO FC III or IV at diagnosis was defined as advanced (AFC) whereas WHO FC I or II were considered as non advanced (NAFC) Results: Mean age was 50.5 years (SD 18) and 79% were female. According with the Nice classification, the distribution was: idiopathic 51.6%, inherited 1,6%, drugs 2.4%, connective tissue disease 15.3%, portal hypertension 1.6% and congenital heart disease 27.4%. WHO FC at initial diagnosis was: I: 3%; II: 27%; III: 45% and IV: 25% and during follow-up was: I: 19%, II 54%, III 21% and IV 6% (p < 0.001). AFC at initial diagnosis was 70% and during follow up 27% (p < 0.001). Clinical manifestations in AFC compared with NAFC was: syncope 11 vs 13% (NS); heart failure 30 vs 4% (p < 0.001); BNP 372 vs 158 pg/ml (0.02), NT-proBNP 1595 vs 668 pg/ml (0.012), TAPSE 17.2 vs 19.3 mm (0.032), pericardial effusion 18 vs 10% (p = 0.020); 6MWT 367 vs 373 (NS); CI 2.6 vs 2.8 (NS); RAP 12.3 vs 10 mm Hg (NS);. PAH targeted drugs in AFC was = None in 26.7%, Monotherapy in 31.4% and Combined therapy in 41.9%. Conclusion: In our registry of PAH, we observed a high percentage of patients with AFC (70%) at initial diagnosis and a significant decrease during follow-up (27%). Advanced FC at initial diagnosis was significantly associated with other variables of poor prognosis. These findings emphasize the need for strategies for early detection and therapy.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are